Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s

Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takaaki Oba, Mark D. Long, Tibor Keler, Henry C. Marsh, Hans Minderman, Scott I. Abrams, Song Liu, Fumito Ito
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/624c24703da040c89811cce847e51d8c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:624c24703da040c89811cce847e51d8c
record_format	dspace
spelling	oai:doaj.org-article:624c24703da040c89811cce847e51d8c2021-12-02T17:32:13ZOvercoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s10.1038/s41467-020-19192-z2041-1723https://doaj.org/article/624c24703da040c89811cce847e51d8c2020-10-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-19192-zhttps://doaj.org/toc/2041-1723Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade.Takaaki ObaMark D. LongTibor KelerHenry C. MarshHans MindermanScott I. AbramsSong LiuFumito ItoNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-20 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Takaaki Oba Mark D. Long Tibor Keler Henry C. Marsh Hans Minderman Scott I. Abrams Song Liu Fumito Ito Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
description	Strategies to increase T cell infiltration within the tumor microenvironment could improve response to immune checkpoint blockade. Here the authors show that a combinatorial regimen based on Flt3L, radiotherapy, and TLR3/CD40 stimulation promotes intratumoral conventional type-1 dendritic cell (cDC1) activation and T cell infiltration, overcoming resistance to PD-L1 blockade.
format	article
author	Takaaki Oba Mark D. Long Tibor Keler Henry C. Marsh Hans Minderman Scott I. Abrams Song Liu Fumito Ito
author_facet	Takaaki Oba Mark D. Long Tibor Keler Henry C. Marsh Hans Minderman Scott I. Abrams Song Liu Fumito Ito
author_sort	Takaaki Oba
title	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
title_short	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
title_full	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
title_fullStr	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
title_full_unstemmed	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s
title_sort	overcoming primary and acquired resistance to anti-pd-l1 therapy by induction and activation of tumor-residing cdc1s
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/624c24703da040c89811cce847e51d8c
work_keys_str_mv	AT takaakioba overcomingprimaryandacquiredresistancetoantipdl1therapybyinductionandactivationoftumorresidingcdc1s AT markdlong overcomingprimaryandacquiredresistancetoantipdl1therapybyinductionandactivationoftumorresidingcdc1s AT tiborkeler overcomingprimaryandacquiredresistancetoantipdl1therapybyinductionandactivationoftumorresidingcdc1s AT henrycmarsh overcomingprimaryandacquiredresistancetoantipdl1therapybyinductionandactivationoftumorresidingcdc1s AT hansminderman overcomingprimaryandacquiredresistancetoantipdl1therapybyinductionandactivationoftumorresidingcdc1s AT scottiabrams overcomingprimaryandacquiredresistancetoantipdl1therapybyinductionandactivationoftumorresidingcdc1s AT songliu overcomingprimaryandacquiredresistancetoantipdl1therapybyinductionandactivationoftumorresidingcdc1s AT fumitoito overcomingprimaryandacquiredresistancetoantipdl1therapybyinductionandactivationoftumorresidingcdc1s
_version_	1718380372653244416

Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s

Ejemplares similares